KR940703803A - 2-아미노-1, 3- 프로판디올 화합물 및 면역 억제제(2-amino-1,3-propanediol compound and immunosupressant) - Google Patents

2-아미노-1, 3- 프로판디올 화합물 및 면역 억제제(2-amino-1,3-propanediol compound and immunosupressant)

Info

Publication number
KR940703803A
KR940703803A KR1019940702174A KR19940702174A KR940703803A KR 940703803 A KR940703803 A KR 940703803A KR 1019940702174 A KR1019940702174 A KR 1019940702174A KR 19940702174 A KR19940702174 A KR 19940702174A KR 940703803 A KR940703803 A KR 940703803A
Authority
KR
South Korea
Prior art keywords
amino
propanediol
substituted
alkyl
ethyl
Prior art date
Application number
KR1019940702174A
Other languages
English (en)
Other versions
KR0155015B1 (ko
Inventor
데쓰로 후지따
시게오 사사끼
마사히꼬 요네따
다다시 미시나
구니또모 아다찌
겐지 지바
Original Assignee
아이야 다다시
요시또미세이야꾸 가부시까기이샤
무찌 후미오
다이또 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26499282&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR940703803(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아이야 다다시, 요시또미세이야꾸 가부시까기이샤, 무찌 후미오, 다이또 가부시끼가이샤 filed Critical 아이야 다다시
Publication of KR940703803A publication Critical patent/KR940703803A/ko
Application granted granted Critical
Publication of KR0155015B1 publication Critical patent/KR0155015B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/18—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with hydroxy groups and at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/20—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/24—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/26—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/34—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton and at least one hydroxy group bound to another carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/72—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/76—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C219/30—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/06—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C07C225/10—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms not being part of rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/31—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/41—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/38—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/30—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/33—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
    • C07C323/34—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a mercapto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

본 발명은 하기식(I)의 2-아미노-1,3-프로판디올 화합물, 그의 약제학적 허용가능한 염 및 이들 화합물을 활성 성분으로 함유하는 면역 억제제에 관한 것이다;
(식중, R은 치환될 수도 있는 직쇄 또는 측쇄 탄소사슬, 치환될 수도 있는 아릴, 치환 될 수도 있는 기크로 알킬 등이고, R2,R3,R4및 R5는 서로 동일 또는 상이하며, 각각은 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐이다.)
본 발명의 2-아미노-1,3-프로판디올 화합물은 면역 억제작용이 있으며, 장기 또는 골수 이식술에서의 거부반응 억제용, 자가면역 질병의 예방치료용 또는 의학 및 약제학 분야 용도의 시약으로서 유용하다.

Description

2-아미노-1,3-프로판디올 화합물 및 면역 억제제(2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPRESSANT)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (49)

  1. 하기식(I)의 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학적 허용가능한 염 ;
    [식중, R은 사슬내에 이중결합, 삼중결합, 산소, 황, 술피닐, 술포닐, -N(R6)-(식중, R6은 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐 기임), 카르보닐, 치환될 수도 있는 아릴렌, 치환될 수도 있는 시클로알킬렌, 치환될 수도 있는 헤테로아릴렌 및 그의 알리시클로 구성된 군으로부터 선택된 단일결합, 헤테로원자 또는 기를 함유할 수 있고 ; 그의 사슬 말단에서 이중결합, 삼중결합, 치환될 수 있는 아릴, 치환될수도 있는 시크로알킬, 치환될 수도 있는 헤테로아릴 또는 그의 알리시클에 의해 치환될 수 있는 치환가능한 직쇄 또는 측쇄 탄소사슬이고 ; 치환 될 수도 있는 아릴, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 또는 그의 알리시클이며 ; R2,R3,R4및 R5는 동일 또는 상이하고, 각각은 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐이거나 R4및 R5는 알킬, 아릴 또는 아랄킬에 의해 치환될 수 있는 알킬렌 사슬을 형성하기 위해 결합할 수 있으며 ; 상기에서 치환될 수도 있는 직쇄-또는 측쇄 탄소사슬은 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 알키렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시이미노, 히드록시, 카르복시, 치환될 수도 있는 아릴, 치환될 수도 있는 아릴옥시, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 및 그의 알리신클로 구성된 군으로부터 선택된 치환기를 가질 수 있으며 ; 상술한 치환될 수도 있는 아릴렌, 치환될 수도 있는 시클로알킬렌, 치환될 수도 있는 헤테로아릴렌 및 그의 알리시클은 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시 및 카르복시로 구성된 군으로부터 선택된 치환기르 가질 수 있고 ; 및 치환될 수도 있는 아릴, 치환될 수도 있는 아릴옥시, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 및 그의 알리시클은 알킬, 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시 및 카르복시로 구성된 군으로부터 선택한 치환기를 지닐 수 있다(이때, R이 C1-C5 알킬일 때, 알킬은 치환되어야 하고, R이 푸릴메틸, 페닐메틸 또는 저급 알킬, 저급 알콕시, 클로로, 히드록시나 아미노에 의해 치환된 페닐메틸일 때, R2와 R3중 하나가 메틸 또는 에틸이 아니라는 조건하임).]
  2. 제1항에 있어서, 하기식(I-1)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학적 허용가능한 염 ;
    [식중, R1은 사슬내에 이중결합, 삼중결합, 산소, 황, 술피닐, 술포닐, -N(R6)-(식중, R6은 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐 기임), 카르보닐, 치환될 수도 있는 아릴렌, 치환될 수도 있는 시클로알킬렌, 치환될 수도 있는 헤테로아릴렌 및 그의 알리시클로 구성된 군으로부터 선택된 단일결합, 헤테로원자 또는 기를 함유할 수 있고 ; 그의 사슬 말단(ω-위치)에서 이중결합, 삼중결합, 치환될 수 있는 아릴, 치환될 수도 있는 시크로알킬, 치환될 수도 있는 헤테로아릴 또는 그의 알리시클에 의해 치환될 수 있는 치환가능한 직쇄-또는 측쇄 탄소사슬이고 ; 치환 될 수도 있는 아릴, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 또는 그의 알리시클이며 ; R2,R3,R4및 R5는 동일 또는 상이하고, 각각은 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐이거나 R4및 R5는 알킬, 아릴 또는 아랄킬에 의해 치환될 수 있는 알킬렌 사슬을 형성하기 위해 결합할 수 있으며 ; 상기에서 치환될 수도 있는 직쇄-또는 측쇄 탄소사슬은 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 알키렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시이미노, 히드록시, 카르복시, 치환될 수도 있는 아릴, 치환될 수도 있는 아릴옥시, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 및 그의 알리시클로 구성된 군으로부터 선택된 치환기를 가질 수 있으며 ; 상술한 치환될 수도 있는 아릴렌, 치환될 수도 있는 시클로알킬렌, 치환될 수도 있는 헤테로아릴렌 및 치환될 수도 있는 아릴, 치환될 수도 있는 아릴옥시, 치환될수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴과 그의 알리시클은 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시 및 카르복시로 구성된 군으로부터 선택된 치환기를 지닐수 있다(이때, R1이 C1-C4 알킬일 때, 알킬은 치환되어야 하고, R1이 푸릴, 페닐 또는 저급 알킬, 저급 알콕시, 클로로, 히드록시나 아미노에 의해 치환된 페닐일 때, R2와 R3중 하나가 메틸 또는 에틸이 아니라는 조건하임).]
  3. 제1항 또는 제2항에 있어서, 하기식 (I-2)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학적 허용가능한 염 ;
    [식중, R1a은 사슬내에 이중결합, 삼중결합, 산소, 황, 술피닐, 술포닐, -N(R6)-(식중, R6은 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐 기임), 카르보닐, 치환될 수도 있는 페닐렌, 치환될 수도 있는 시클로알킬렌으로 구성된 군으로부터 선택된 단일결합, 헤테로원자 또는 기를 함유할 수 있는 치환가능한 직쇄-또는 측쇄 탄소사슬이고 ; 치환 될 수도 있는 페닐 또는 치환될 수도 있는 시클로알킬이며 ; 및 R2a,R3a,R4a 및 R5a는 서로 동일 또는 상이하고, 각각은 수소, 알킬, 아실 또는 알콕시카르보닐이며 ; 여기서 , 치환될 수도 있는 페닐 및 치환될 수도 있는 시클로알킬은 이중결합, 삼중결합, 산소 황, 술피닐, 술포닐 -N(R6)-(이때, R6는 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐 기임), 카르보닐, 치환될 수도 있는 페닐렌, 치환될 수도 있는 시클로알킬렌으로 구성된 군으로부터 선택된 단일결합, 헤테로원자 또는 기를 사슬내에 가질수 있는 치환될 수도 있는 직쇄-또는 측쇄 탄소사슬로 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 알키렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 니트로, 할로겐, 아미노, 히드록시, 카르복시, 치환될 수도 있는 페닐, 치환될 수도 있는 페녹시 및 치환될 수도 있는 시클로알킬로 구성된 군으로부터 선택된 치환기를 가질 수 있고 ; 치환 될 수도 있는 탄소사슬은 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 니트로, 할로겐, 아미노, 히드록시 및 카르복시, 치환될 수도 있는 페닐, 치환될 수도 있는 페녹시 및 치환될 수도 있는 시클로알킬로 구성된 군으로부터 선택된 치환기를 가질수 있으며 ; 및 상술한 치환될 수도 있는 페닐렌, 치환될 수도 있는 시클로알킬렌, 치환될 수도 있는 페닐, 치환될 수도 있는 페녹시 및 치환될 수도 있는 시클로알킬은 알콕시, 알케닐옥시, 알키닐옥시, 알랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 니트로, 할로겐, 아미노, 히드록시 및 카르복시로 구성된 군으로부터 선택한 치환기를 가질 수 있다(이때, R1a가 C1-C4 알킬일 때, 알킬은 치환되어야 하고, R1a가 푸릴, 페닐 또는 저급 알킬, 저급 알콕시, 클로로, 히드록시나 아미노에 의해 치환된 페닐일 때, R2a와 R3a중 하나가 메틸 또는 에틸이 아니라는 조건하임).]
  4. 제3항에 있어서, 하기식 (I-3)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학적 허용가능한 염 ;
    [식중, R1b는 치환될 수도 있는 알킬, 치환될 수도 있는 알케닐, 치환될 수도 있는 알키닐, 치환될 수도 있는 페닐 또는 치환될 수도 있는 시클로알킬이고 R2b,R3b,R4b 및 R5b는 서로 동일 또는 상이하고 각각은 수소, 알킬, 또는 아실이며 ; 여기서 치환될 수도 있는 알킬, 치환될 수도 있는 알케닐 및 치환될 수도 있는 알키닐은 알콕시, 알케닐옥시, 알키닐옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 니트로, 할로겐, 아미노, 히드록시 및 카르복시, 치환될 수도 있는 페닐, 치환될 수도 있는 시클로알킬로 구성된 군으로부터 선택된 치환기를 가질 수 있고 ; 및 상술한 치환될 수도 있는 페닐과 치환될 수도 있는 시클로알킬은 알킬, 알케닐, 알키닐, 알콕시, 알케닐옥시, 알키닐옥시, 알랄킬옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 니트로, 할로겐, 아미노, 히드록시 및 카르복시로 구성된 군으로부터 선택한 1∼3개의 치환기를 가질 수 있다(이때, R1b가 C1-C4 알킬일 때, 알킬은 치환되어야 하고, R1b가 푸릴, 페닐 또는 저급 알킬, 저급 알콕시, 클로로, 히드록시 또는 아미노로 치환된 페닐일 때, R2b와 R3b중 하나가 메틸 또는 에틸이 아니라는 조건하임).]
  5. 제1항 내지 제4항중 어느 한 항에 있어서, 하기식(I-4)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    [식중, Ra는 사슬내에 이중결합, 삼중결합, 산소, 황, 술피닐, 술포닐, -N(R6)-(이때, R6는 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐임) 및 카르보닐로 구성된 군으로부터 선택된 헤테로원자 또는 단일결합을 가질 수 있으며, 치환기로서 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 니트로, 할로겐, 아미노, 히드록시이미노, 히드록시 또는 카르복시를 가질 수 있는 탄소수 12∼22개의 직쇄-또는 측쇄 알킬이고, 및 R2b,R3b,R4b 및 R5b는 동일 또는 상이하고, 각각은 수고, 알킬 또는 아실이다.]
  6. 제5항에 있어서, 하기식(I-5)을 가지고 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    [식중, Rb는 사슬내에 산소원자를 가질 수 있고, 치환기로서 니트로, 할로겐, 아미노, 히드록시 또는 카르복시를 가질 수 있는 탄소원자 13∼20개의 직쇄-또는 측쇄 알킬이고, R2c 및 R3c는 동일 또는 상이하고, 각각은 수소 또는 알킬임]
  7. 제5항 또는 제6항에 있어서, 하기식(I-6)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    [식중, Rc는 탄소원자 13∼20개의 직쇄 또는 측쇄 알킬이거나 할로겐에 의해 치환된 탄소원자 13∼20개의 직쇄-또는 측쇄 알킬임]
  8. 제5항 내지 제7항중 어느 한항에 있어서, 하기로 구성된 군으로부터 선택된 2-아미노-1,3-프로판디올 화합물 및 그의 약제학상 허용가능한 염 ; 2-아미노-2-트리데실-1,3-프로판디올, 2-아미노-2-테트라데실-1,3-프로판디올, 2-아미노-2-펜타데실-1,3-프로판디올, 2-아미노-2-헥사데실-1,3-프로판디올, 2-아미노-2-헵타데실-1,3-프로판디올, 2-아미노-2-옥타데실-1,3-프로판디올, 2-아미노-2-노나데실-1,3-프로판디올, 2-아미노-2-이코실-1,3-프로판디올, 2-아미노-2-(12-플루오로도데실)-1,3-프로판디올 및 2-아미노-2-(14-플루오로테트라데실)-1,3-프로판디올.
  9. 제1항 내지 제4항중 어느 한 항에 있어서, 하기식(I-7)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    [식중, Rd는 페닐알킬, 치환된 페닐알킬, 시클로알킬알킬, 치환된 시클로알킬알킬, 헤테로아릴알킬, 치환된 헤테로아릴알킬, 헤테로시클릭알킬 또는 치환된 헤테로시클릭알킬이고, 이때, 알킬부분은 탄소사슬내 이중결합, 삼중결합, 산소, 황, 술피닐, 술포닐, -N(R6)-(이때, R6는 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐임)과 카르보닐로 구성된 군으로부터 선택된 단일결합) 또는 헤테로원자이고, 치환기로서 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 니트로, 할로겐, 아미노, 히드록시 또는 카르복시를 가질 수 있고 ; 및 치환된 페닐알킬, 치환된 시클로알킬알킬, 치환된 헤테로아릴알킬 및 치환된 헤테로시클릭알킬은 알킬, 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 할로아랄킬옥시, 아랄킬옥시알킬, 페녹시알킬, 페녹시알콕시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시 및 카르복시로 구성된 군으로부터 선택된 치환기를 가질 수 있다.]
  10. 제9항에 있어서, 하기식(I-8)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    [식중, Re는 알킬부분이 탄소원자 6∼20개인 직쇄-또는 측쇄의 페닐알킬 ; 할로겐에 의해 치환가능한 직쇄-또는 측쇄의 C6-C20알킬, 할로겐에 의해 치환가능한 직쇄-또는 측쇄의 C6-C20알콕시, 직쇄-또는 측쇄의 C6-C20알케닐옥시, 페닐알콕시, 할로페닐알콕시, 페닐알콕시알킬, 페녹시알콕시 또는 페녹시알킬에 의해 치환될 수 있는 페닐알킬 ; 알킬부분이 탄소원자 6∼20개의 직쇄-또는 측쇄의 시클로알킬알킬 ; 탄소원자 6∼20개인 직쇄-또는 측쇄의 알킬에 의해 치환된 시클로알킬알킬 ; 알킬부분이 탄소원자 6∼20개인 직쇄-또는 측쇄의 헤테로아릴알킬 ; 탄소원자 6∼20개인 직쇄-또는 측쇄 알킬에 의해 치환된 헤테로아릴알킬 ; 알킬부분이 탄소원자 6∼20개인 직쇄-또는 측쇄이거나 탄소원자 6∼20개인 직쇄-측쇄 알킬에 의해 치환된 헤테로시클릭알킬이다(이때, 알킬부분은 탄소사슬내에 이중결합, 삼중결합, 산소, 황, 술피닐, 술포닐, -N(R6)-(이때, R6는 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐임)과 카르보닐로 구성된 군으로부터 선택한 단일결합 또는 헤테로원자이고, 치환기로서 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 니트로, 할로겐, 아미노, 히드록시 또는 카르복시를 가질 수 있다)]
  11. 제9항 또는 제10항에 있어서, 하기식 (I-9)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    [식중, Rf는 알킬부분이 탄소원자 6∼20개인 직쇄-또는 측쇄로 탄소사슬내에 1 또는 2개의 산소원자를 가지는 페닐알킬 ; 할로겐에 의해 치환가능한 직쇄-또는 측쇄 C6-C20알킬, 할로겐에 의해 치환가능한 직쇄-또는 측쇄의 C6-C20알콕시, 직쇄-또는 측쇄의 C6-C20알케닐옥시, 페닐알콕시, 할로페닐알콕시, 페닐알콕시알킬, 페녹시알콕시 또는 페녹시알킬에 의해 치환될 수 있는 페닐알킬 ; 알킬부분이 탄소원자 6∼20개의 직쇄-또는 측쇄로, 탄소사슬내에 1 또는 2개의 산소원자를 가질 수 있는 시클로알킬알킬 ; 탄소원자 6∼20개인 직쇄-또는 측쇄의 알킬에 의해 치환된 시클로알킬알킬 ; 알킬부분이 탄소원자 6∼20개인 직쇄-또는 측쇄로, 탄소사슬내에 1 또는 2개의 산소원자를 가질 수 있는 헤테로아릴알킬 ; 탄소원자 6∼20개인 직쇄-또는 측쇄 알킬에 의해 치환된 헤테로아릴알킬 ; 알킬부분이 탄소원자 6∼20개인 직쇄-또는 측쇄 알킬에 의해 치환된 헤테로아릴알킬 ; 알킬부분이 탄소원자 6∼20개인 직쇄-또는 측쇄로, 탄소사슬내에 1 또는 2개의 산소원자를 가질 수 있는 헤테로시클릭 알킬 또는 탄소원자 6∼20개인 직쇄-또는 측쇄 알킬에 의해 치환된 헤테로시클릭알킬이고 ; 이때, 알킬부분은 탄소사슬내에 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 니트로, 할로겐, 아미노, 히드록시 또는 카르복시로 구성된 군으로부터 선택한 치환기를 가질 수 있다)]
  12. 제9항 내지 제11항중 어느 한 항에 있어서, 하기식 (I-10)을 가지는 2-아미노-1,3-프로판디올화합물 또는 그의 약제학상 허용가능한 염 ;
    [식중, Rg는 알킬부분이 탄소원자 6∼20개인 직쇄-또는 측쇄로, 탄소사슬내에 1 또는 2개의 산소원자를 가질 수 있는 페닐알킬 ; 할로겐에 의해 치환가능한 직쇄-또는 측쇄 C6-C14알킬, 할로겐에 의해 치환가능한 직쇄-또는 측쇄의 C6-C14알콕시, 직쇄-또는 측쇄의 C6-C14알케닐옥시, 페닐알콕시, 할로페닐알콕시, 페닐알콕시알킬, 페녹시알콕시 또는 페녹시알킬에 의해 치환될 수 있는 페닐알킬 ; 알킬부분에 탄소원자 6∼20개를 가지는 시클로알킬알킬 ; 탄소원자 6∼20개인 직쇄-또는 측쇄 알킬에 의해 치환된 시클로알킬알킬 ; 알킬부분에 탄소원자 6∼20개를 가지는 헤테로아릴알킬 ; 탄소원자 6∼14개인 직쇄-또는 측쇄 알킬에 의해 치환된 헤테로아릴알킬 ; 알킬부분에 탄소원자 6∼20개인 헤테로아릴알킬 ; 알킬부분에 탄소원자 6∼20개인 헤테로시클릭알킬 또는 탄소원자 6∼20개인 직쇄-또는 측쇄 알킬에 의해 치환된 헤테로시클릭알킬이다]
  13. 제12항에 있어서, 하기식(I-11)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학적 허용가능한 염 :
    [식중, Rh는 아킬부분에 탄소원자가 6∼20개인 페닐알킬, 알킬부분과 알콕시부분에 전체 탄소원자가 6∼20개인 페닐알콕시알킬, 알킬부분에 탄소원자가 6∼20개인 페녹시알킬 또는 알킬부분과 알콕시부분에 전체 탄소원자가 6∼20개인 페녹시알콕시알킬이다]
  14. 제13항에 있어서, 하기로 구성된 군으로부터 선택한 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    1-아미노-2-(8-페닐옥틸)-1,3-프로판디올, 2-아미노-2-(9-페닐노닐)-1,3-프로판디올, 2-아미노-2-(10-페닐데실)-1,3-프로판디올, 2-아미노-2-(11-페닐운데실)-1,3-프로판디올, 2-아미노-2-(12-페닐도데실)-1,3-프로판디올, 2-아미노-2-(13-페닐트리데실)-1,3-프로판디올, 2-아미노-2-(14-페닐테트라데실)-1,3-프로판디올, 2-아미노-2-(15-페닐펜타데실)-1,3-프로판디올, 2-아미노-2-(16-페닐헥사데실)-1,3-프로판디올, 2-아미노-2-[6-(8-페닐옥틸옥시)헥실]-1,3-프로판디올, 2-아미노-2-(8-페닐메틸옥시옥틸)-1,3-프로판디올, 2-아미노-2-(9-페녹시노닐)-1,3-프로판디올, 2-아미노-2-(12-페녹시도데실)-1,3-프로판디올 및 2-아미노-2-[6-(2-페녹시에틸옥시)헥실]-1,3-프로판디올.
  15. 제13항에 있어서, 하기로 구성된 군으로부터 선택한 2-아미노-1,3-프로판디올 또는 그의 약제학상 허용가능한 염 :
    2-아미노-2-(10-페닐데실)-1,3-프로판디올, 2-아미노-2-(13-페닐트리데실)-1,3-프로판디올, 2-아미노-2-[6-(8-페닐옥틸옥시)헥실]-1,3-프로판디올, 2-아미노-2-(8-페닐메틸옥시옥틸)-1,3-프로판디올, 2-아미노-2-(9-페녹시노닐)-1,3-프로판디올, 2-아미노-2-(12-페녹시도데실)-1,3-프로판디올 및 2-아미노-2-[6 -2-페녹시에틸옥시)헥실]-1,3-프로판디올.
  16. 제12항에 있어서, 하기식 (I-12)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, Ri는 할로겐으로 치환가능한 직쇄-또는 측쇄 C6-C14알킬, 할로겐에 의해 치환가능한 직쇄-또는 측쇄 C6-C14알콕시 또는 직쇄-또는 측쇄 C6-C14알케닐옥시에 의해 치환된 페닐알킬이고 ; 페닐알킬중 알킬부분은 히드록시에 의해 치환가능하다]
  17. 제16항에 있어서, 하기식 (I-13)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, Rj는 할로겐에 의해 치환가능한 직쇄-또는 측쇄 C6-C14알킬, 할로겐에 의해 치환가능한 직쇄-또는 측쇄 C6-C14알콕시 또는 직쇄-또는 측쇄 C6-C14알케닐옥시에 의해 치환된 페닐알킬이다(식중 알킬부분은 히드록시에 의해 치환가능한 C2-C6알킬임).]
  18. 제16항 또는 제17항에 있어서, 하기의 군으로부터 선택한 직쇄-또는 측쇄2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    2-아미노-2-[2-(4-헵틸페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-옥틸페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-노닐페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-데실페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-운데실페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-도데실페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-트리데실페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-테트라데실페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-헥실옥시페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-헵틸옥시페닐)에틸]-1, 3-프로판디올, 2-아미노-2-[2-(4-옥틸옥시페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-노닐옥시페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-데실옥시페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-운데실옥시페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-도데실옥시페닐)에틸]-1,3-프로판디올, 2-아미노-2-[ 2-(4-트리데실옥시페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(8-플루오로옥틸)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(12-플루오로도데실)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(7-플루오로헵틸옥시)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(11-플루오로운데실옥시)페닐)에틸]-1,3-프로판디올 및 2-아미노-2-[2-(4-(7-옥테닐옥시)페닐)에틸]-1,3-프로판디올.
  19. 제16항 또는 제17항에 있어서, 하기로 구성된 군으로부터 선택한 2-아미노-1,3-프로판디올 화합물또는 그의 약제학상 허용가능한 염 :
    2-아미노-2-[2-(4-헵틸페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-옥틸페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-노닐페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-데실페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-운데실페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-도데실페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-헵틸옥시페닐)에틸]-1, 3-프로판디올, 2-아미노-2-[2-(4-옥틸옥시페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-노닐옥시페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-운데실옥시페닐)에틸]- 1,3-프로판디올, 및 2-아미노-2-[2-(4-(7-옥테닐옥시)페닐)에틸]-1,3-프로판디올.
  20. 제12항에 있어서, 하기식(I-14)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, Rk는 페닐알콕시, 할로페닐알콕시, 페닐알콕시알킬, 페녹시알콕시 또는 페녹시알킬에 의해 치환된 페닐알킬이다.]
  21. 제20항에 있어서, 하기식(I-15)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, Rl은 알콕시부분에 탄소원자 2∼8개인 페닐알콕시, 알콕시부분에 탄소원자가 2∼8개인 할로페닐알콕시, 알콕시부분과 알킬부분에 전체 탄소원자가 2∼8개인 페닐알콕시알킬, 알콕시부분에 탄소원자가 2∼8개인 페녹시알콕시 또는 알킬부분에 탄소원자가 2∼8개인 페녹시 알킬에 의해 치환된, 알킬부분에 2∼6개인 탄소원자를 가지는 페닐알킬이다]
  22. 제20항 또는 제21항에 있어서, 하기로 구성된 군으로부터 선택한 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    2-아미노-2-[2-(4-페닐메틸옥시페닐)에틸]1,3-프로판디올, 2-아미노-2-[2-(4-(2-페닐에틸옥시)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(3-페닐프로필옥시)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-( 4-(4-페닐부틸옥시)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(5-페닐펜틸옥시)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(6-페닐헥실옥시))에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(7-페닐헵틸옥시)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(8-페닐옥틸옥시)페닐)에틸]-1,3-프로판디올, 2-아미노-2- [4-(6-(4-플루오로페닐)헥실옥시)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(5-페닐펜틸옥시메틸)페닐)에틸]-1, 3-프로판디올, 2-아미노-2-[2-(4-(4-페녹시부틸옥시)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(5-페녹시펜틸옥시)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(6-페녹시헥실옥시)페닐)에틸 ]-1,3-프로판디올, 2-아미노-2-[2-(4-(7-페녹시헵틸옥시)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4- (4-페녹시부틸)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[ 2-(4-(5-페녹시펜틸)페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(6-페녹시헥실)페닐)에틸]-1,3-프로판디올 및 2-아미노-2-[2-(4-(7-페녹시헵틸)페닐)에틸]-1,3-프로판디올.
  23. 제20항 또는 제21항에 있어서, 하기로 구성된 군으로부터 선택한 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    2-아미노-2-[2-(4-(6-페닐헥실옥시)페닐)에틸]-1,3-프로판디올 및 2-아미노-2-[2-(4-(5-페닐펜틸옥시메틸)페닐)에틸]-1,3-프로판디올.
  24. 제12항에 있어서, 하기식(I-16)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, Rm은 알킬부분에 전체 탄소원자가 6∼20개인 알킬-치환된 시클로알킬이다]
  25. 제24항에 있어서, 하기로 구성딘 군으로부터 선택한 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    2-아미노-2-[3-(4-헵틸시클로헥실)프로필]-1,3-프로판디올. 2-아미노-2-[4-(4-부틸시클로헥실)부틸]-1, 3-프로판디올, 2-아미노-2-[2-(4-옥틸시클로헥실)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-노닐시클로헥실)에틸]-1,3-프로판디올 및 2-아미노-2-[2-(4-도데실시클로헥실)에틸]-1,3-프로판디올.
  26. 제12항에 있어서, 하기식(I-17)을 가지는 2-아미노-1,3-프로판이올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, Rn은 알킬부분에 전체 탄소원자가 6∼20개인 1-알킬-치환된 피페리딘-4-일알킬이다]
  27. 제26항에 있어서, 하기로 구성된 군으로부터 선택한 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    2-아미노-2-[2-(1-옥틸피페리딘-4-일)에틸]-1,3-프로판디올 및 2-아미노-2-[2-(1-도데실피페리딘-4-일)에틸]-1,3-프로판디올.
  28. 제12항에 있어서, 하기식(i-18)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, Ro는 알킬부분에 탄소원자가 6∼20개인 티에닐알킬, 알킬부분에 전체 탄소원자가 6∼20개인 알킬-치환된 티에닐알킬, 알킬부분에 탄소원자가 6∼20개인 피리딜알킬 또는 알킬부분에 전체 탄소원자가 6∼20개인 알킬-치환된 피리딜알킬이다]
  29. 제28항에 있어서, 하기로 구성된 군으로부터 선택한 2-아미노-1,3-프로판디올 화합물 및 그의 약제학상 허용가능한 염 :
    2-아미노-2-[2-(5-옥틸-2-티에닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(5-노닐-2-티에닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(5-데실-2-티에닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(5-도데실-2-티에닐)에틸]-1,3-프로판디올, 2-아미노-2-[13-(2-티에닐)트리데실]-1,3-프로판디올, 2-아미노-2-[2-(5-옥틸-2-피리딜)에틸]-1,3-프로판디올, 2-아미노-2-[2-(5-데실-2-피리딜)에틸]-1,3-프로판디올, 2-아미노-2- [13-(2-피리딜)트리데실]-1,3-프로판디올,2-아미노-2-[2-(2-옥틸-5-피리딜)에틸]-1,3-프로판디올 2-아미노-2-[2-(2-데실-2-피리딜)에틸]-1,3-프로판디올 및 2-아미노-2-[13-(3-필리딜)트리데실]-1,3-프로판디올.
  30. 제1항 또는 제2항에 있어서, 하기식(I-19)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, Rp는 C6-C18알킬, 시클로알킬, 헤테로아릴 또는 헤테로시클에 의해 치환된 페닐이다]
  31. 제30항에 있어서, 하기식(I-20)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    [식중, Rq는 C6-C18알킬에 의해 치환된 페닐이다]
  32. 제30항 또는 제31항에 있어서, 하기로 구성된 군으로부터 선택한 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    2-아미노-2-(4-데실페닐)-1,3-프로판디올, 2-아미노-2-(4-도데실페닐)-1,3-프로판디올, 2-아미노-2- (4-테트라데실페닐)-1,3-프로판디올 및 2-아미노-2-(4-헥사데실페닐)-1,3-프로판디올.
  33. 제1항 또는 제2항에 있어서, 하기식(I-21)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, R1은 사슬내에 이중결합, 삼중결합, 산소, 황, 술피닐, 술포닐, -N(R6)-(식중, R6은 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐 기임) 및 카르보닐, 치환될 수 있는 아릴렌, 치환될 수도 있는 시클로알킬렌, 치환될 수도 있는 헤테로아릴렌 및 그의 알리시클로 구성된 군으로부터 선택된 단일결합, 헤테로원자 또는 기를 함유할 수 있고 ; 그의 사슬 말단(ω-위치)에는 이중결합, 삼중결합, 치환될 수도 있는 아릴, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 또는 그의 알리시클에 의해 치환될 수 있는 치환가능한 직쇄-또는 측쇄 탄소사슬이며 ; 치환될 수도 있는 아릴, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 또는 그의 알리시클이고 ; 및 R2a,R3a,R4a 및 R5a는 동일 또는 상이하고, 각각은 수소, 알킬, 아실 또는 알콕시카르보닐이며 ; 상기에서 치환될 수도 있는 직쇄-또는 측쇄 탄소사슬은 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시이미노, 히드록시 또는 카르복시, 치환될 수도 있는 아릴, 치환될 수도 있는 아릴옥시, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 및 그의 알리시클로 구성된 군으로부터 선택된 치환기를 가질 수 있으며 ; 상술한 치환될 수도 있는 아릴렌, 치환될 수도 있는 시클로알킬렌, 치환될 수도 있는 헤테로아릴렌 및 그의 알리시클, 치환될 수도 있는 아릴, 치환될 수도 있는 아릴옥시, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴과 그의 알리시킬은 알콕시, 알케닐옥시, 알키닐옥시, 알랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시 및 카르복시로 구성된 군으로부터 선택한 치환기를 가질 수도 있다.]
  34. 제33항에 있어서, 하기식(I-22)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, Rr은 사슬내 이중결합이나 카르보닐을 가질 수 있으며, 히드록시 및/또는 히드록시이미노에 의해 치환가능한 알킬이다]
  35. 제33항 또는 제34항에 있어서, 하기로 구성된 군으로부터 선택한 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    2-아미노-2-(1,2,12-트리히드록시-4-옥타데세닐)-1,3-프로판디올, 2-아미노-2-(1,2-디히드록시-4-옥타데세닐)-1,3-프로판디올, 2-아미노-2-(1,2-디히드록시옥타데세닐)-1,3-프로판디올, 2-아미노-2-(1,12-디히드록시-4-옥타데세닐)-1,3-프로판디올, 2-아미노-2-1,2,4-트리히드록시부틸)-1,3-프로판디올, 2-아미노-2-(1,2,12-트리히드록시옥타데세닐)-1,3-프로판디올 및 2-아미노-2-(1,12-디히드록시옥타데세닐)-1,3-프로판디올.
  36. 제33항에 있어서, 하기식 (I-23)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, Rs는 할로겐에 의해 치환가능한 직쇄-또는 측쇄 C6-C14알킬, 할로겐에 의해 치환가능한 직쇄-또는 측쇄 C6-C14알콕시 또는 직쇄-또는 측쇄 C6-C14알케닐옥시에 의해 치환된 페닐알킬이다]
  37. 제36항에 있어서, 하기로 구성된 군으로부터 선택한 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    2-아미노-2-[1-히드록시-2-(4-옥틸페닐)에틸]-1,3-프로판디올, 2-아미노-2-(2-(4-도데실페닐)-1-히드록시에틸]-1,3-프로판디올, 2-아미노-2-(2-(4-헵틸옥시페닐)-1-히드록시에틸]-1,3-프로판디올, 2-아미노-2-[1-히드록시-2-(4-운데실옥시페닐)에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(8-플루오로옥틸)페닐)-1 -히드록시에틸]-1,3-프로판디올, 2-아미노-2-(2-(4-(12-플루오로도데실)페닐)-1-히드록시에틸]-1,3-프로판디올, 2-아미노-2-[2-(4-(7-플루오로헵틸옥시)페닐)-1-히드록시에틸]-1,3-프로판디올 및 2-아미노-2- [1-히드록시-2-(4-(11-플루오로운데실옥시)페닐)에틸]-1,3-프로판디올.
  38. 제1항 또는 제2항에 있어서, 하기식(I-24)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    [식중, Rt는 사슬내에 이중결합, 삼중결합, 산소, 황, 술피닐, 술포닐, -N(R6)-(식중, R6은 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐 기임), 카르보닐, 치환될 수도 있는 아릴렌, 치환될 수 있는 시클로알킬렌, 치환될 수도 있는 헤테로아릴렌 및 그의 알리시클, 치환될 수도 있는 아릴, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 또는 그의 알리시클로 구성된 군으로부터 선택한 단일결합, 헤테로원자 또는 기를 함유할 수 있는 치환가능한 직쇄-또는 측쇄 사슬이고, R2a,R3a,R4a 및 R5a는 동일 또는 상이하고, 각각은 수소, 알킬, 아실 또는 알콕시카르보닐이며 ; 상기에서 치환될 수도 있는 직쇄-또는 측쇄 탄소사슬은 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시, 카르복시, 치환될 수도 있는 아릴, 치환될 수도 있는 아릴옥시, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 및 그의 알리시클로 구성된 군으로부터 선택된 치환기를 가질 수 있으며 ; 상술한 치환될 수도 있는 아릴렌, 치환될 수도 있는 시클로알킬렌, 치환될 수도 있는 헤테로아릴렌 및 그의 알리시클, 치환될 수도 있는 아릴, 치환될 수도 있는 아릴옥시, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴과 그의 알리시킬은 알콕시, 알케닐옥시, 알키닐옥시, 알랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시 및 카르복시로 구성된 군으로부터 선택한 치환기를 가질 수도 있다.]
  39. 제38항에 있어서, 하기식(I-25)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, Ru는 탄소원자가 4∼16개인 알킬에 의해 치환된 페닐이다]
  40. 제 38항 또는 제39항에 있어서, 하기로 구성된 군으로부터 선택한 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    2-아미노-2-[2-(4-옥틸페닐)에테닐)-1,3-프로판디올, 2-아미노-2-[2-(4-데실페닐)에테닐]-1,3-프로판디올, 2-아미노-2-[2-(4-도데실페닐)에테닐]-1,3-프로판디올 및 2-아미노-2-[2-(4-테트라데실페닐)에테닐]-1,3-프로판디올.
  41. 제1항 또는 제2항에 있어서, 하기식(I-26)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    [식중, Rv는 치환가능한 아릴, 치환가능한 시클로알킬, 치환가능한 헤테로아릴 또는 그의 알리시클이고 ; R2a,R3a,R4a 및 R5a는 동일 또는 상이하고, 각각은 수소, 알킬, 아실 또는 알콕시카르보닐이며 ; X는 산소, 황, 술피닐, 술포닐, -N(R6)-(여기서, R6은 수소 알킬, 아랄킬, 아실 또는 알콕시카르보닐)이며 ; 및 α와 β는 α+β=5∼20이고, 이때 치환가능한 아릴, 치환가능한 시클로알킬, 치환가능한 헤테로아릴 및 그의 알리시클이 알킬, 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시 및 카르복시로 구성된 군으로부터 선택된 치환기를 가질 수 있다는 조건하에서 0또는 1∼20의 정수이다]
  42. 제41항에 있어서, 하기식(I-27)을 가지는 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 :
    [식중, Rw는 C4-C16알킬에 의해 치환된 페닐이다]
  43. 제41항 또는 제42항에 있어서, 하기로 구성된 군으로부터 선택한 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염 ;
    2-아미노-2-(4-옥틸페녹시메틸)-1,3-프로판디올, 2-아미노-2-(4-데실페녹시메틸)-1,3-프로판디올, 2-아미노-2-(4-도데실페녹시메틸)-1,3-프로판디올 및 2-아미노-2-(4-테트라데실페녹시메틸)-1,3-프로판디올.
  44. 제1항 내지 제4항중 어느 하나를 함유하는 약제학적 조성물.
  45. 하기식(I-28)의 2-아미노-1,3-프론판디올 화합물 또는 그의 약제학상 허용가능한 염을 포함하는 면역 억제제 ;
    [식중, R은 사슬내에 이중결합, 삼중결합, 산소, 황, 술피닐, 술포닐, -N(R6)-(식중, R6은 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐 기임), 카르보닐, 치환될 수도 있는 아릴렌, 치환될 수 있는 시클로알킬렌, 치환될 수도 있는 헤테로아릴렌 및 그의 알리시클로 구성된 군으로부터 선택한 단일결합, 헤테로원자 또는 기를 가질 수 있고 ; 그의 사슬 말단에는 이중결합, 삼중결합, 치환될 수도 있는 아릴, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 또는 그의 알리시클에 의해 치환될 수 있는 치환가능한 직쇄-또는 측쇄 탄소사슬이고 ; 치환될 수도 있는 아릴, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 또는 그의 알리시클이며 ; R2,R3,R4및 R5는 동일 또는 상이하고, 각각은 수소, 알킬, 아랄킬, 아실 또는 알콕시카르보닐이거나 R4및 R5는 알킬, 아릴 또는 아랄킬에 의해 치환될 수 있는 알킬렌 사슬에 의해 결합할 수 있으며 ; 상기에서 치환될 수도 있는 직쇄-또는 측쇄 탄소사슬은 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시, 카르복시, 치환될 수도 있는 아릴, 치환될 수도 있는 아릴옥시, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 및 그의 알리시클로 구성된 군으로부터 선택된 치환기를 가질 수 있으며 ; 상술한 치환될 수도 있는 아릴렌, 치환될 수도 있는 시클로알킬렌, 치환될 수도 있는 헤테로아릴렌 및 그의 알리시클은 알콕시, 알케닐옥시, 알키닐옥시, 알랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시 및 카르복시로 구성된 군으로부터 선택된 치환기를 가질 수 있고 ; 및 치환될 수도 있는 아릴, 치환될 수도 있는 아릴 옥시, 치환될 수도 있는 시클로알킬, 치환될 수도 있는 헤테로아릴 및 그의 알리시클은 알킬, 알콕시, 알케닐옥시, 알키닐옥시, 아랄킬옥시, 알킬렌디옥시, 아실, 알킬아미노, 알킬티오, 아실아미노, 알콕시카르보닐, 알콕시카르보닐아미노, 아실옥시, 알킬카르바모일, 할로알킬, 할로알콕시, 니트로, 할로겐, 아미노, 히드록시 및 카르복시로 구성된 군으로부터 선택한 치환기를 지닐 수 있다]
  46. 제1항 내지 제43항중 어느 한 항에 있어서, 2-아미노-1,3-프로판디올 화합물 또는 그의 약제학상 허용가능한 염을 함유하는 면역 억제제.
  47. 제45항 또는 제46항에 있어서, 면역 억제제가 거부반응의 억제제인 약제.
  48. 제45항 또는 제46항에 있어서, 면역 억제제가 자가면역 질병의 예방 치료제인 약제.
  49. 제49항에 있어서, 자가면역 질병의 예방 치료제가 류마티즘의 예방치료제인 약제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940702174A 1992-10-21 1993-10-18 2-아미노-1,3-프로판디올 화합물 및 면역 억제제 KR0155015B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP92-283281 1992-10-21
JP28328192 1992-10-21
JP93-179427 1993-07-20
JP17942793 1993-07-20
PCT/JP1993/001515 WO1994008943A1 (en) 1992-10-21 1993-10-18 2-amino-1,3-propanediol compound and immunosuppressant

Publications (2)

Publication Number Publication Date
KR940703803A true KR940703803A (ko) 1994-12-12
KR0155015B1 KR0155015B1 (ko) 1998-12-01

Family

ID=26499282

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702174A KR0155015B1 (ko) 1992-10-21 1993-10-18 2-아미노-1,3-프로판디올 화합물 및 면역 억제제

Country Status (13)

Country Link
US (3) US5604229A (ko)
EP (1) EP0627406B1 (ko)
JP (1) JP2579602B2 (ko)
KR (1) KR0155015B1 (ko)
AT (1) ATE172711T1 (ko)
CA (1) CA2126337C (ko)
CY (2) CY2215B1 (ko)
DE (2) DE122011100012I1 (ko)
DK (1) DK0627406T3 (ko)
ES (1) ES2126658T3 (ko)
HK (1) HK1013281A1 (ko)
LU (1) LU91832I2 (ko)
WO (1) WO1994008943A1 (ko)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
PT778263E (pt) * 1994-08-22 2002-06-28 Mitsubishi Pharma Corp Composto de benzeno e sua utilizacao farmaceutica
ATE279185T1 (de) * 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
EP0990440B1 (en) 1997-02-27 2008-10-29 Novartis AG Pharmaceutical composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharide
ATE298740T1 (de) 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
WO1999001420A1 (fr) 1997-07-03 1999-01-14 Taito Co., Ltd. Procede de preparation de derives d'acide 2-aminomalonique, et intermediaires utilises dans ce procede
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
PT1457478T (pt) * 1998-11-11 2017-10-26 Mitsubishi Pharma Corp Produção de 2-amino-2-[2-(4-alquil-fenil)etil]propano-1,3-dióis
CN1144779C (zh) * 1999-03-11 2004-04-07 杭州中美华东制药有限公司 制备2-[2-(4-烷基苯基)-乙基]-2-氨基-丙二醇的方法以及其中制得的中间产物
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
CA2379993A1 (en) * 1999-07-30 2001-02-08 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
MXPA03000397A (es) 2000-07-13 2003-05-27 Sankyo Co Derivados de aminoalcohol.
CN100415735C (zh) * 2000-07-13 2008-09-03 三共株式会社 氨基醇衍生物
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
WO2002029001A2 (en) * 2000-10-03 2002-04-11 University Of Virginian Patent Foundation Novel lysophosphatidic acid receptor agonists and antagonists
JP2004529100A (ja) * 2001-01-30 2004-09-24 ユニバーシティ オブ バージニア パテント ファウンデーション スフィンゴシン−１−ホスフェートレセプターのアゴニストおよびアンタゴニスト
PT1368015E (pt) * 2001-02-22 2006-12-29 Novartis Ag Utilização de agentes de alojamento linfocitário acelerado no fabrico de um medicamento para o tratamento da função de enxerto retardada
ATE314383T1 (de) 2001-03-26 2006-01-15 Novartis Pharma Gmbh 2-amino-propanol derivate
CN1524002A (zh) * 2001-06-08 2004-08-25 ��˹��ŵ�� 治疗或预防产胰岛素细胞的移植排斥反应
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
JP4152884B2 (ja) * 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
MXPA04002679A (es) * 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
BR0306811A (pt) 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
EP1469863A2 (en) * 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
US20040014662A1 (en) 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
KR20120125398A (ko) 2002-05-16 2012-11-14 노파르티스 아게 암에서 ｅｄｇ 수용체 결합제의 용도
CN100351244C (zh) 2002-05-27 2007-11-28 诺瓦提斯公司 双芳族链烷醇
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
CA2497067A1 (en) 2002-09-13 2004-03-25 Novartis Ag Amino-propanol derivatives
CA2498944C (en) * 2002-09-19 2011-05-17 Yasushi Kohno Amino alcohol derivatives, salts thereof and immunosuppressive agents
KR20080103117A (ko) * 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
HUE028247T2 (en) * 2003-04-08 2016-12-28 Novartis Ag A solid oral composition comprising S1P receptor agonist and sugar alcohol
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
WO2005013958A1 (en) * 2003-08-07 2005-02-17 Novartis Ag Histone deacetylase inhibitors as immunosuppressants
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
MXPA06002310A (es) * 2003-08-29 2006-05-25 Ono Pharmaceutical Co Compuesto capaz de enlazarse al receptor s1p y uso farmaceutico del mismo.
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0324210D0 (en) * 2003-10-15 2003-11-19 Novartis Ag Organic compounds
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물
EP2363149A1 (en) 2004-05-03 2011-09-07 Novartis AG Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
EP1750722A4 (en) * 2004-05-06 2010-03-10 Univ Virginia NEW LYSOPHOSPHIC ACID RECEPTORSELECTIVE ANTAGONISTS
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
PL1772145T3 (pl) * 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym
JP4919374B2 (ja) * 2004-07-29 2012-04-18 第一三共株式会社 免疫抑制剤としての医薬組成物
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
AU2005266449B2 (en) * 2004-07-30 2009-10-08 Novartis Ag Compound formulations of 2-amino-1,3-propanediol compounds
WO2006020951A1 (en) * 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
US20060223866A1 (en) * 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
KR101181090B1 (ko) * 2004-10-12 2012-09-07 교린 세이야꾸 가부시키 가이샤 2-아미노-2-［2-［4-(3-벤질옥시페닐티오)-2-클로로페닐］에틸］-1,3-프로판디올 염산염 또는 그 수화물의 제조방법 및 그 제조 중간체
JP2008521827A (ja) * 2004-11-29 2008-06-26 ノバルティス アクチエンゲゼルシャフト Ｓ１ｐ受容体アゴニストの投与レジメン
JP5021488B2 (ja) 2004-12-21 2012-09-05 メルク セローノ ソシエテ アノニム スルホニルアミノ環式誘導体及びその使用
DK1844032T3 (da) 2005-01-31 2011-10-24 Merck Serono Sa N-hydroxyamid-derivater og deres anvendelse
BRPI0607740A2 (pt) * 2005-02-08 2009-09-29 Novartis Ag indução de anticorpos antilinfócitos
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
SI1889198T1 (sl) 2005-04-28 2015-02-27 Proteus Digital Health, Inc. Farma-informacijski sistem
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
WO2007022718A1 (en) * 2005-08-25 2007-03-01 Chunde Liu Alkyl aryl alkyl alcohols, their derivations and preparation process thereof
CA2616479A1 (en) * 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
PT1932522E (pt) * 2005-10-07 2012-06-26 Kyorin Seiyaku Kk Agente terapêutico para doenças do fígado contendo, como princípio activo, um derivado de 2- amino-1,3-propanodiol
CN1310869C (zh) * 2005-11-22 2007-04-18 江苏吴中苏药医药开发有限责任公司 2－氨基－2－[2－(4－烷基苯基)乙基]－1,3－丙二醇的制备方法
PL1961734T3 (pl) * 2005-12-15 2012-02-29 Mitsubishi Tanabe Pharma Corp Związek aminowy i jego zastosowanie do celów medycznych
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
ES2543840T3 (es) 2006-04-11 2015-08-24 Novartis Ag Inhibidores espirocíclicos del VHC/VIH y sus usos
WO2007126042A1 (ja) 2006-04-28 2007-11-08 Mitsubishi Tanabe Pharma Corporation ２－アミノブタノール化合物及びその医薬用途
US20090324581A1 (en) 2006-05-09 2009-12-31 Daiichi Sankyo Company Limited Heteroarylamide lower carboxylic acid derivative
WO2007129473A1 (ja) * 2006-05-09 2007-11-15 Daiichi Sankyo Company, Limited 二環性アリール誘導体
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
TW200815600A (en) 2006-08-04 2008-04-01 Daiichi Sankyo Co Ltd An enzyme for phosphorizing a medicine
NZ574011A (en) * 2006-08-08 2011-10-28 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
MY146775A (en) 2006-08-08 2012-09-28 Kyorin Seiyaku Kk Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
MX2009002893A (es) 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
KR20090057399A (ko) 2006-09-26 2009-06-05 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
CA2690686C (en) 2007-06-14 2013-08-06 Mitsubishi Tanabe Pharma Corporation Amine compound and pharmaceutical use thereof
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
WO2009048993A2 (en) 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
AU2008319397B2 (en) * 2007-11-01 2013-01-31 Acucela, Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
IL187247A0 (en) 2007-11-08 2008-12-29 Hadasit Med Res Service Novel synthetic analogs of sphingolipids
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
WO2009115954A1 (en) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
RU2529474C2 (ru) 2008-03-19 2014-09-27 Новартис Аг Способ получения 2-амино-2-[2-(4-с3-с21-алкилфенил)этил]пропан-1, 3-диолов
JP5451746B2 (ja) 2008-04-16 2014-03-26 アンガス ケミカル カンパニー ニトロ化炭化水素、誘導体及びそれらの製造プロセス
BRPI0907318B1 (pt) * 2008-04-16 2018-06-19 Angus Chemical Company Processo para a formação seletiva de 2- nitropropano e 2,2- dinitropropano
CN104800196A (zh) 2008-06-20 2015-07-29 诺华股份有限公司 用于治疗多发性硬化的儿科组合物
KR20110073580A (ko) 2008-10-17 2011-06-29 엑셀리시스, 인코포레이티드 스핑고신-1-포스페이트 수용체 길항제
CA2739901A1 (en) * 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
AR074062A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica
AU2013100532B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
JP2012508216A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
BRPI0921533A2 (pt) 2008-11-11 2016-01-12 Novartis Ag composto orgânicos
SI3409274T1 (sl) 2008-12-22 2020-03-31 Novartis Ag Režim odmerjanja za S1P receptor agonist
WO2010087244A1 (ja) * 2009-01-30 2010-08-05 第一三共株式会社 アミノアルコール環状化合物
CN102333530A (zh) * 2009-02-24 2012-01-25 诺瓦提斯公司 神经酰胺类似物代谢物
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
NZ596876A (en) 2009-05-06 2014-01-31 Lab Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
EP2456752A2 (en) 2009-07-24 2012-05-30 ratiopharm GmbH Process for producing fingolimod salts
WO2011041145A2 (en) 2009-09-29 2011-04-07 Novartis Ag Method and system for accessing patient data
CA2780859A1 (en) * 2009-12-10 2011-06-16 Novartis Ag Fty720 halogenated derivatives
EP2560619A2 (en) 2010-04-22 2013-02-27 Ratiopharm GmbH A method of preparing an oral dosage form comprising fingolimod
CA2797042A1 (en) 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod in the form of a solid solution
EP2560618A1 (en) 2010-04-22 2013-02-27 Ratiopharm GmbH Melt-granulated fingolimod
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2621889B1 (en) 2010-10-01 2019-07-17 Synthon BV Process for making fingolimod hydrochloride crystals
WO2012041359A1 (en) 2010-10-01 2012-04-05 Synthon B.V. Process for making fingolimod
BR112013008510A2 (pt) 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
JP2014503478A (ja) 2010-10-28 2014-02-13 マピ ファーマ リミテッド フィンゴリモドの調製のための中間の化合物およびプロセス
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
ES2746016T3 (es) 2010-12-28 2020-03-04 Synthon Bv Procedimiento para la preparación de cristales de clorhidrato de fingolimod
US8673308B2 (en) 2011-02-23 2014-03-18 Als Therapy Development Institute Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases
EP2505589A1 (en) 2011-04-01 2012-10-03 Johann Wolfgang Goethe-Universität Frankfurt am Main Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
WO2012146980A2 (en) 2011-04-29 2012-11-01 Dr. Reddy's Laboratories Ltd. Preparation of fingolimod and its salts
CN103930101A (zh) 2011-08-03 2014-07-16 马忠民 用fty720治疗2型糖尿病
AU2012298567B2 (en) * 2011-08-19 2017-07-06 Westfaelische Wilhelms-Universitaet Muenster New ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases
WO2013055907A1 (en) * 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US8946301B2 (en) 2011-11-29 2015-02-03 Als Therapy Development Institute Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
EP2609912A1 (en) 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Pharmaceutical combination of fingolimod and nabiximols
EP2804605A4 (en) * 2012-01-20 2015-07-08 Acucela Inc SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES
EP2807143B1 (en) * 2012-01-25 2017-08-30 Glenmark Generics Limited Process for preparation of fingolimod
EP2842937B1 (en) 2012-04-23 2018-01-17 Mitsubishi Tanabe Pharma Corporation Amine compound and use thereof for medical purposes
CZ2012406A3 (cs) * 2012-06-15 2013-12-27 Zentiva, K.S. Způsob výroby fingolimodu založený na otevírání aziridinového kruhu
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CN103539683A (zh) * 2012-07-17 2014-01-29 广东东阳光药业有限公司 治疗硬化病的药物的新晶型及其制备方法
MX2015004806A (es) * 2012-10-19 2015-11-18 Ruth Perez Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
WO2014111836A1 (en) 2013-01-17 2014-07-24 Shilpa Medicare Limited Process for preparation of fingolimod and its salts
WO2014111949A1 (en) 2013-01-21 2014-07-24 Natco Pharma Limited Intermediates and process for the preparation of high purity fingolimod hydrochloride
JP6484567B2 (ja) * 2013-03-05 2019-03-13 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ ２−アミノ−１，３−プロパンジオール化合物およびその塩の製造のための方法
EP2990055B1 (en) 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
CA2920758A1 (en) 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
KR101820330B1 (ko) 2013-10-11 2018-01-19 테이코쿠 팔마 유에스에이, 인코포레이티드 국소 스핑고신-1-포스페이트 수용체 효현제 제형 및 이의 사용 방법
US20170165236A1 (en) 2013-11-01 2017-06-15 Celgene International Ii Sàrl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
EP3074374B1 (en) 2013-11-25 2019-03-13 Emcure Pharmaceuticals Limited Fingolimod hydrochloride process
WO2015107548A1 (en) 2014-01-07 2015-07-23 Emcure Pharmaceuticals Limited Improved fingolimod process
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US20180250235A1 (en) 2015-09-18 2018-09-06 Sanovel Ilac Sanayi Ve Ticaret A.S. Fingolimod capsule composition
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
US10865163B2 (en) 2017-12-20 2020-12-15 The University Of Toledo Carbon dioxide as a directing group for C—H functionalization reactions involving Lewis basic amines, alcohols, thiols, and phosphines for the synthesis of compounds
WO2020165672A1 (en) 2019-02-15 2020-08-20 Shivalik Rasayan Limited Process for preparation of highly pure fingolimod hydrochloride
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US20230348665A1 (en) * 2020-08-01 2023-11-02 Cornell University Chelation crosslinked polymers, methods of making same, and uses thereof
CN113072471B (zh) * 2021-03-02 2022-09-16 四川美大康华康药业有限公司 一种利非司特中间体及其制备方法
CN113577059B (zh) * 2021-08-02 2022-05-20 山东大学齐鲁医院(青岛) 一种用于小儿哮喘的活性药物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3062839A (en) * 1959-06-11 1962-11-06 American Home Prod Dihydroxy-tertiary-butylamines
US3426042A (en) * 1963-09-26 1969-02-04 Union Carbide Corp Organic cyclic carbonates
US3432603A (en) * 1964-10-19 1969-03-11 Sterling Drug Inc Process for weight reduction
US3324043A (en) * 1964-10-19 1967-06-06 Sterling Drug Inc Anti-oxidant compositions and process
US3660488A (en) * 1965-07-16 1972-05-02 Phillips Petroleum Co 2-halo-alkylene- and -cyclopentylene-2-amino-propane 1 3-diols
US3928572A (en) * 1971-02-11 1975-12-23 Ayerst Mckenna & Harrison Myriocin and process of preparation
JPS5154565A (ko) * 1974-11-02 1976-05-13 Toa Eiyo Kagaku Kogyo Kk
JPS6050186B2 (ja) * 1980-07-15 1985-11-07 三井東圧化学株式会社 ２−メルカプトエチルアミンハロゲン化水素酸塩類の製造法
JPS6050783B2 (ja) * 1981-03-20 1985-11-11 三井東圧化学株式会社 Ｓ，ｓ′−ビス（２−アミノエチル）ジチオカ−ボネ−トジハイドロハライド誘導体の製造方法
JPS58101108A (ja) * 1981-12-11 1983-06-16 Unitika Ltd キレ−ト形成基を有するフエノ−ル樹脂とその製造方法及び吸着処理方法
DE3420308C2 (de) * 1983-05-31 1998-06-18 Toyo Boseki Polyurethanzusammensetzung mit verbesserten Färbeeigenschaften
US4910218A (en) * 1985-11-22 1990-03-20 Burroughs Wellcome Co. Phenanthro[2,3-6]thiophene derivatives, pharmaceutical compositions and use
JPS632904A (ja) * 1986-06-20 1988-01-07 Ss Pharmaceut Co Ltd 植物生長調節剤
JPS6343140A (ja) * 1986-08-08 1988-02-24 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料の処理方法
US5068247A (en) * 1989-07-07 1991-11-26 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopentanoic acid compounds and their use as immunosuppressants
EP0450527A3 (en) * 1990-03-30 1991-10-30 Kao Corporation N-tris(hydroxymethyl)methylfatty acid amides and cosmetic compositions containing same
JPH049309A (ja) * 1990-04-25 1992-01-14 Kao Corp 化粧料
JPH0469320A (ja) * 1990-07-06 1992-03-04 Kao Corp 毛髪化粧料
JP2868887B2 (ja) * 1990-11-06 1999-03-10 花王株式会社 薬用化粧料
JPH04224548A (ja) * 1990-12-26 1992-08-13 Kao Corp 脂肪酸アミドの製造方法
JPH06509559A (ja) * 1991-03-19 1994-10-27 セラピューティック　パッチ　リサーチ　エヌ．ブイ． 膜透過エンハンサーとしてのアミノアルコール誘導体組成物及び方法
JPH0578294A (ja) * 1991-09-19 1993-03-30 Kao Corp 分岐脂肪酸アミド並びにその製造方法及び製造中間体

Also Published As

Publication number Publication date
EP0627406B1 (en) 1998-10-28
WO1994008943A1 (en) 1994-04-28
EP0627406A4 (en) 1995-04-12
DE69321823T2 (de) 1999-06-02
CY2011006I2 (el) 2016-12-14
US5719176A (en) 1998-02-17
ES2126658T3 (es) 1999-04-01
CY2215B1 (en) 2003-04-18
DE69321823D1 (de) 1998-12-03
EP0627406A1 (en) 1994-12-07
CA2126337C (en) 2003-06-24
CY2011006I1 (el) 2016-12-14
DE122011100012I1 (de) 2011-10-20
LU91832I2 (fr) 2011-08-30
DK0627406T3 (da) 1999-07-12
JP2579602B2 (ja) 1997-02-05
US5952316A (en) 1999-09-14
US5604229A (en) 1997-02-18
HK1013281A1 (en) 1999-08-20
KR0155015B1 (ko) 1998-12-01
CA2126337A1 (en) 1994-04-28
ATE172711T1 (de) 1998-11-15

Similar Documents

Publication Publication Date Title
KR940703803A (ko) 2-아미노-1, 3- 프로판디올 화합물 및 면역 억제제(2-amino-1,3-propanediol compound and immunosupressant)
JP6833844B2 (ja) アルギナーゼ活性を阻害する組成物及び方法
JP7339997B2 (ja) ベンズアゾール化合物ならびに該化合物の作製方法および使用方法
ES2651843T3 (es) Derivados de pirazolopirrolidina y su uso en el tratamiento de enfermedades
ES2543216T3 (es) Moduladores de tiazolopirimidina como agentes inmunosupresores
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
TWI395749B (zh) 吡咯并〔１，２-ｂ〕嗒酮化合物
US20220288070A1 (en) Deuterated mk2 pathway inhibitors and methods of using the same
CA2986344A1 (en) Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CA2994258A1 (en) Prodrugs of glutamine analogs
BR112020008850A2 (pt) composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
HRP20180199T1 (hr) Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1)
JP2019504050A5 (ko)
RU2016118768A (ru) Композиции, пригодные для лечения расстройств, связанных с kit
BRPI0713187A2 (pt) método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
KR870007137A (ko) 치환 피리딘술폰아미드 화합물, 이들을 함유하는 제초 조성물 및 이들 화합물의 제조 방법.
RU2012129168A (ru) Производные оксазина
JP2010100637A5 (ko)
TR201816387T4 (tr) Bisiklik heterosikllerin antiviral aktivitesi.
ES2594378T3 (es) Derivados de la bencilidenoguanidina y uso terapéutico para el tratamiento de enfermedades por mal plegamiento proteico
ES2222396T3 (es) Compuestos utiles como ingrediente activo de un medicamento para el tratamiento preventivo y/o terapeutico de enfermedades neurodegenerativas.
CN102596959A (zh) 吡咯并[1,2-b]哒嗪衍生物作为janus激酶抑制剂
CZ113692A3 (en) Quinoxalines, process of their preparation and their use
JP2018513190A5 (ko)
US20190054097A1 (en) Compositions targeting senescent cells and the uses thereof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130619

Year of fee payment: 16

FPAY Annual fee payment

Payment date: 20130826

Year of fee payment: 20

EXPY Expiration of term